TERT, the target?

Since 2013, when 2 hotspot point mutations were identified in the telomerase reverse transcriptase (TERT) promoter in melanomas, this genetic event was found to be among the most common point mutations in several tumor entities.^1–5 Thus, TERT is in the research focus of many scientists in different branches of oncology. For neuro-oncology, it is of pivotal interest due to its high frequencies in several brain tumors, most notably glioblastoma and oligodendroglioma.^4,6